News
In a report released on May 30, analyst Jason McCarthy from Maxim Group maintained a Buy rating on CERo Therapeutics Holdings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback